Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
Conte B, Bruzzone M, Lambertini M, Poggio F, Bighin C, Blondeaux E, De Laurentiis M, Valle E, Cognetti F, Nisticò C, De Placido S, Garrone O, Gamucci T, Montemurro F, Puglisi F, Cardinali B, Fregatti P, Miglietta L, Boccardo F, Ceppi M, Del Mastro L; GIM2 Investigators.
Conte B, et al. Among authors: cardinali b.
Eur J Cancer. 2020 Sep;136:43-51. doi: 10.1016/j.ejca.2020.05.007. Epub 2020 Jul 4.
Eur J Cancer. 2020.
PMID: 32634760
Clinical Trial.